Category: 73591-69-2

Balzarini, J.; De Clercq, E. published an article in 1982, the title of the article was Structure-function relationship of the antitumor cell activity of pyrimidine and pyridine derivatives.Recommanded Product: 73591-69-2 And the article contains the following content:

Fifty-two 2′-deoxyuridines, 10 2′-deoxycytidines, uracil arabinoside  [3083-77-0] and 7 analogs, cytosine arabinoside  [147-94-4] and 7 analogs, 5 nicotinic acid analogs, and 4 nicotinamide analogs were compared for their inhibitory effects on murine leukemia (L1210) cell growth. The most dramatic antitumor activity was demonstrated by the deoxyuridine analogs containing a small C5-substituent with high electron-withdrawing potency, i.e., F-, CF3-, ethynyl, or formyl. The deoxycytidine analogs were generally less active, with the 5-nitro- [69100-02-3] and 5-ethynyl [69075-47-4] analogs having the greatest effect. Of the 5-substituted uracil arabinosides, only the 5-Me analog [605-23-2] significantly inhibited L1210 growth. Cytosine arabinoside and its 5-fluoro analog [4298-10-6] were highly effective inhibitors. Of the nicotinic acid derivatives, only the m-propyl- [73591-68-1] and m-isopropyl [73591-69-2] derivatives showed weak antitumor activity. The meta- and para-alkylated nicotinamide derivatives also had weak activity. The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Recommanded Product: 73591-69-2

The Article related to antitumor pyridine pyrimidine derivative structure, structure activity pyridine pyrimidine derivative, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 73591-69-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 15, 1980, Freyne, Eddy J.; Esmans, Eddy L.; Lepoivre, Josef A.; Alderweireldt, Frank C. published an article.Name: 5-Isopropylnicotinic acid The title of the article was Stereospecific synthesis of a novel series of pyridine nucleosides. And the article contained the following:

Condensation of 3,5-di-O-benzoyl-β-D-ribofuranosyl chloride severally with 3-acetyl-5-alkylpyridines, 5-alkyl-3-methoxycarbonylpyridines (alkyl = Me, Et, Pr, and Me2CH), 5-isopropylnicotinamide, and 3,5-diacetylpyridine bis(ethylene acetal) in MeCN at -5° gave the corresponding 1-(3,5-di-O-benzoyl-β-D-ribofuranosyl)-3,5-disubstituted pyridinium chlorides in excellent yield (90%). From the reaction of a series of 2,3-O-isopropylidene-β-D-ribofuranosyl halides with 3-acetyl-5-methylpyridine at room temperature, the α-nucleosides were obtained. The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Name: 5-Isopropylnicotinic acid

The Article related to pyridine nucleoside, stereospecific ribosylation pyridine, Carbohydrates: Nucleosides, Nucleotides and other aspects.Name: 5-Isopropylnicotinic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 4, 2021, Behenna, Douglas; Deckhut, Charlotte; Rovira, Alexander; Goldberg, Steven; Kummer, David; Keith, John; Woods, Craig; Rhorer, Timothy; Tanis, Virginia; Martin, Connor; Meduna, Steven; McCarver, Stefan; Valdes, Alexander; Loskot, Steven; Xue, Xiaohua published a patent.Safety of 5-Isopropylnicotinic acid The title of the patent was Imidazopyridazines as modulators of IL-17 in the treatment of inflammatory disorders. And the patent contained the following:

The invention relates compounds of formula I, preparation and use in treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease. Compound I, wherein R1 is (un)substituted C1-6 alkyl, (un)substituted C0-2 alkyl-C3-6 cycloalkyl, and (un)substituted 5- and 6-membered heterocyclyl having 1 and 2 nitrogen atoms; R2 is H, C3-5 cycloalkyl and (un)substituted C1-4 alkyl; R3 is (un)substituted C0-1 alkyl-C3-6 cycloalkyl, (un)substituted C3-6 alkyl and (un)substituted C1-2 alkyl-O-C1-3 alkyl; R4 is (un)substituted C3-6 cycloalkyl, (un)substituted Ph and (un)substituted 5- and 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O and S; R5 is H and halo; and pharmaceutically acceptable salts thereof, are claimed. Compound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for IL-17A modulatory activity resulting in an IC50 of 0.18μM and 0.30μM using Eu-HTRF and NHK assays, resp. Compounds of the invention were evaluated for IL-17A modulatory activity (data given). The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Safety of 5-Isopropylnicotinic acid

The Article related to imidazopyridazine preparation modulator il 17 inflammatory disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Safety of 5-Isopropylnicotinic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 4, 2021, Behenna, Douglas; Deckhut, Charlotte; Rovira, Alexander; Goldberg, Steven; Kummer, David; Keith, John; Woods, Craig; Rhorer, Timothy; Tanis, Virginia; Martin, Connor; Meduna, Steven; McCarver, Stefan; Valdes, Alexander; Loskot, Steven; Xue, Xiaohua published a patent.Safety of 5-Isopropylnicotinic acid The title of the patent was Imidazopyridazines as modulators of IL-17 in the treatment of inflammatory disorders. And the patent contained the following:

The invention relates compounds of formula I, preparation and use in treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease. Compound I, wherein R1 is (un)substituted C1-6 alkyl, (un)substituted C0-2 alkyl-C3-6 cycloalkyl, and (un)substituted 5- and 6-membered heterocyclyl having 1 and 2 nitrogen atoms; R2 is H, C3-5 cycloalkyl and (un)substituted C1-4 alkyl; R3 is (un)substituted C0-1 alkyl-C3-6 cycloalkyl, (un)substituted C3-6 alkyl and (un)substituted C1-2 alkyl-O-C1-3 alkyl; R4 is (un)substituted C3-6 cycloalkyl, (un)substituted Ph and (un)substituted 5- and 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O and S; R5 is H and halo; and pharmaceutically acceptable salts thereof, are claimed. Compound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for IL-17A modulatory activity resulting in an IC50 of 0.18μM and 0.30μM using Eu-HTRF and NHK assays, resp. Compounds of the invention were evaluated for IL-17A modulatory activity (data given). The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Safety of 5-Isopropylnicotinic acid

The Article related to imidazopyridazine preparation modulator il 17 inflammatory disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Safety of 5-Isopropylnicotinic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 1, 1981, Dommisse, Roger; Freyne, Eddy; Esmans, Eddy; Lepoivre, Josef; Alderweireldt, Frank published an article.Product Details of 73591-69-2 The title of the article was Carbon-13 NMR shift increments for 3-substituted pyridines. And the article contained the following:

The 13C NMR spectra of sixteen 3-substituted and 3,5-disubstituted pyridines are assigned. The substituent shift increment for the 3-Ac group is reassigned, and new shift increments for 3- and 5-substituents are proposed. The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Product Details of 73591-69-2

The Article related to nmr pyridine substituent effect, acetylpyridine carbon nmr, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Product Details of 73591-69-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem